Patients with tumours expressing activated PLD1/mTOR signalling may be sensitive to rapamycin-based therapies; however, it has been shown that high levels of PLD1 confers rapamycin resistance in MDA-MB-231 breast cancer cells in vitro (Chen et al, 2003). Here, MTOR is linked to breast cancer.